SCHEMBL16796852

SCHEMBL16796852

O=C1CCC(c2ccccc2OC(F)F)N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
KMT2A Q03164 1/20 0.41
NR1I2 O75469 1/20 0.41
TSHR P16473 4/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
PKM P14618 1/20 0.38
ADRA1A P35348 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
SCN9A Q15858 1/20 0.37
DRD1 P21728 1/20 0.36
GAA P10253 1/20 0.36
IKBKB O14920 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16796850 1.00 ATM (0.47) ATMALDH1A1KDM4EKMT2ANR1I2
SCHEMBL16796941 1.00 ATM (0.47) ATMALDH1A1KDM4EKMT2ANR1I2
SCHEMBL16796888 0.80 L3MBTL1 (0.54) ATMALDH1A1KDM4EKMT2APOLB
SCHEMBL16796750 0.80 ALDH1A1 (0.45) ATMALDH1A1KDM4EKMT2ANR1I2
SCHEMBL16796809 0.79 ALDH1A1 (0.47) ATMALDH1A1KDM4EKMT2ANR1I2
SCHEMBL18150779 0.79 ALDH1A1 (0.47) ATMALDH1A1KDM4EKMT2ANR1I2
SCHEMBL16796807 0.79 ALDH1A1 (0.47) ATMALDH1A1KDM4EKMT2ANR1I2
SCHEMBL4536209 0.77 HCRTR2 (0.45) ATMALDH1A1KMT2ATSHR
SCHEMBL24282772 0.74 TNKS2 (0.42) ALDH1A1KMT2ASCN9AGAAIKBKB
SCHEMBL31198369 0.73 TACR1 (0.46) ALDH1A1KDM4EKMT2ANR1I2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3080121-B1 FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2019-09-04 EP disclosed
US-9932343-B2 Fused tricyclic benzimidazoles derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2018-04-03 US disclosed
CN-105814048-B Fused tricyclic benzimidizole derivatives as TNF active regulators UCB生物制药私人有限公司 2018-03-27 CN disclosed
US-20160304523-A1 Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity SANOFI (FR) 2016-10-20 US disclosed
EP-3080121-A1 FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2016-10-19 EP disclosed
CN-105814048-A Fused tricyclic imidazole derivatives as modulators of TNF activity UCB生物制药私人有限公司 2016-07-27 CN disclosed
WO-2015086525-A1 FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304523-A1 Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity TNF, TNFRSF1A, TNFRSF9 ATM 2581/4885ALDH1A1 205/4885KDM4E 4047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.